Steven Cohen's XENE Position Overview
Steven Cohen (via Point72 Asset Management, L.P.) currently holds 130,378 shares of Xenon Pharmaceuticals Inc. (XENE) worth $7.87 M, representing 0.01% of the portfolio. First purchased in 2015-Q1, this long-term strategic position has been held for 43 quarters.
Based on 13F filings since 2013, Steven Cohen has maintained a long-term strategic position in XENE, representing a significant commitment to this investment thesis. Largest addition occurred in Q4 2021, adding 1.91 M shares. Largest reduction occurred in Q2 2022, reducing 1.24 M shares.
Analysis based on 13F filings available since 2013 Q2
Steven Cohen's Xenon Pharmaceuticals (XENE) Holding Value Over Time
Track share changes against reported price movement
Quarterly Xenon Pharmaceuticals (XENE) Trades by Steven Cohen
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | +130,378 | New Buy | 130,378 | $60.36 |
| Q2 2025 | -209,759 | Sold Out | 0 | $0.00 |
| Q1 2025 | +209,759 | New Buy | 209,759 | $33.55 |
| Q4 2024 | -383,290 | Sold Out | 0 | $0.00 |
| Q3 2024 | -98,732 | Reduce 20.48% | 383,290 | $39.37 |
| Q2 2024 | +206,163 | Add 74.73% | 482,022 | $38.99 |
| Q1 2024 | -599,206 | Reduce 68.48% | 275,859 | $43.05 |
| Q4 2023 | -250,643 | Reduce 22.27% | 875,065 | $46.06 |
| Q3 2023 | +977,500 | Add 659.55% | 1.13 M | $34.16 |
| Q2 2023 | -356,416 | Reduce 70.63% | 148,208 | $38.50 |
| Q1 2023 | -673,700 | Reduce 57.17% | 504,624 | $35.79 |
| Q4 2022 | -461,748 | Reduce 28.15% | 1.18 M | $39.43 |
| Q3 2022 | +738,566 | Add 81.93% | 1.64 M | $36.10 |
| Q2 2022 | -1.24 M | Reduce 58.00% | 901,506 | $30.42 |
| Q1 2022 | -846,147 | Reduce 28.27% | 2.15 M | $30.57 |
| Q4 2021 | +1.91 M | Add 177.66% | 2.99 M | $31.24 |
| Q3 2021 | +175,500 | Add 19.45% | 1.08 M | $15.28 |
| Q2 2021 | +141,299 | Add 18.57% | 902,300 | $18.62 |
| Q1 2021 | +288,022 | Add 60.90% | 761,001 | $17.90 |
| Q4 2020 | +25,918 | Add 5.80% | 472,979 | $15.38 |
| Q3 2020 | -212,343 | Reduce 32.20% | 447,061 | $11.07 |
| Q2 2020 | +74,351 | Add 12.71% | 659,404 | $12.54 |
| Q1 2020 | -270,747 | Reduce 31.64% | 585,053 | $11.34 |
| Q4 2019 | -69,200 | Reduce 7.48% | 855,800 | $13.11 |
| Q2 2019 | +75,000 | Add 8.82% | 925,000 | $9.86 |
| Q1 2019 | +125,000 | Add 17.24% | 850,000 | $10.16 |
| Q4 2018 | +325,000 | Add 81.25% | 725,000 | $6.31 |
| Q3 2018 | +321,900 | Add 412.16% | 400,000 | $13.20 |
| Q2 2018 | -228,979 | Reduce 74.57% | 78,100 | $9.21 |
| Q1 2018 | -3,100 | Reduce 1.00% | 307,079 | $4.90 |
| Q4 2016 | -48,352 | Reduce 13.49% | 310,179 | $7.70 |
| Q1 2016 | +41,146 | Add 12.96% | 358,531 | $6.99 |
| Q3 2015 | +50,045 | Add 18.72% | 317,385 | $8.26 |
| Q2 2015 | +157,340 | Add 143.04% | 267,340 | $11.53 |
| Q1 2015 | +110,000 | New Buy | 110,000 | $16.86 |
Steven Cohen's Xenon Pharmaceuticals Investment FAQs
Steven Cohen first purchased Xenon Pharmaceuticals Inc. (XENE) in Q1 2015, acquiring 110,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Steven Cohen has held Xenon Pharmaceuticals Inc. (XENE) for 43 quarters since Q1 2015.
Steven Cohen's largest addition to Xenon Pharmaceuticals Inc. (XENE) was in Q4 2021, adding 2,992,597 shares worth $93.49 M.
According to the latest 13F filing for Q2 2026, Steven Cohen's firm, Point72 Asset Management, L.P., owns 130,378 shares of Xenon Pharmaceuticals Inc. (XENE), valued at approximately $7.87 M.
As of the Q2 2026 filing, Xenon Pharmaceuticals Inc. (XENE) represents approximately 0.01% of Steven Cohen's publicly disclosed stock portfolio, making it one of their key holdings.
Steven Cohen's peak holding in Xenon Pharmaceuticals Inc. (XENE) was 2,992,597 shares, as reported at the end of Q4 2021.